Document:

Exh_10_13

		
			Exhibit 10.13
		

		
			 
		

		
			 
		

		
			CONSULTING AGREEMENT
		

		
			 
		

		
			THIS CONSULTING AGREEMENT (the “Agreement”), made this 8th day of August, 2012 is entered into by LS22, Inc., a Delaware corporation with its principal place of business at One Memorial Drive, 7th Floor, Cambridge, MA 02142 (the “Company”), and Richard A. Young, PhD., (the “Consultant”). The Consultant is a Member of the Whitehead Institute for Biomedical Research (“WIBR”) and faculty member in the Department of Biology of the Massachusetts Institute of Technology (“MIT”).
		

		
			 
		

		
			INTRODUCTION
		

		
			 
		

		
			The Company desires to retain the services of the Consultant and the Consultant desires to perform certain services for the Company. In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows:
		

		
			 
		

		
			1.        Services. The Consultant agrees to perform such consulting, advisory and related services to and for the Company as may be reasonably requested from time to time by the Company. The Consultant agrees to devote up to one (1) day per week to the performance of such services. Without limiting the additional terms and conditions of Section 7 below, during the Consultation Period (as defined below), the Consultant shall not knowingly engage in any activity that has a conflict of interest with the Company, including any competitive employment, business, or other activity, and he shall not knowingly assist any other person or organization that competes, or intends to compete, with the Company,  it being further acknowledged and understood by the Company that Consultant is currently involved in those endeavors listed on Annex 1 hereto.
		

		
			 
		

		
			The Whitehead Institute Uniform Consulting Agreement Provisions (“Standard Provisions”) are attached hereto as Exhibit A and are incorporated herein by reference. The parties agree that the Standard Provisions are an integral part of this Agreement and this Agreement shall have no force or effect unless the Standard Provisions are signed by both parties. The parties hereto agree to abide by such Standard Provisions and further agree that in the event of any conflict between this Agreement and the Standard Provisions, the Standard Provisions shall govern and prevail.
		

		
			 
		

		
			2.        Term. This Agreement shall commence on the date hereof and shall continue until August 8, 2016 (such period, as it may be extended, being referred to as the “Consultation Period”), unless sooner terminated in accordance with the provisions of Section 4.
		

		
			 
		

		
			3.        Compensation.
		

		
			 
		

		
			3.1        Equity Compensation. Subject to approval by the Board of Directors of the Company, in consideration for the performance of the services hereunder, the Consultant shall be awarded a grant of 1,600,000 shares of restricted common stock, $0.001 par value per share, of the Company (“Common Stock”), having a purchase price equal to the fair market value of the Common Stock on the date of grant ($0.001 per share) and having such other terms and conditions, including with respect to forfeiture and other transfer restrictions in favor of the Company, as shall be set forth in a Restricted Stock Agreement by and between the Consultant and the Company.
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			3.2        Fees. The Company will not pay the Consultant any consulting fees before the Qualified Financing Date (as defined below). After the Qualified Financing Date and before the Second Qualified Financing Date (as defined below), the Company shall pay to the Consultant consulting fees of $25,000 per year, payable in equal quarterly installments. From and after the Second Qualified Financing Date, the Company shall pay to the Consultant consulting fees of $50,000 per year, payable in equal quarterly installments. Payment for any partial quarter shall be prorated.
		

		
			 
		

		
			For purposes of this Agreement, “Qualified Financing Date” shall mean the first date on which the Company receives aggregate gross proceeds equal to or exceeding $750,000 from the sale to one or more third parties of shares of its capital stock, or notes or other indebtedness that is convertible into or exercisable for shares of its capital stock, in a venture capital transaction. For purposes of this Agreement, “Second Qualified Financing Date” shall mean the first date on which the Company receives aggregate gross proceeds equal to or exceeding $12,500,000 from the sale to one or more third parties of its capital stock, or notes or other indebtedness that is convertible into or exercisable for shares of its capital stock, in a venture capital transaction.
		

		
			 
		

		
			3.3        Reimbursement of Expenses. The Company shall reimburse the Consultant for all reasonable and necessary expenses incurred or paid by the Consultant in connection with, or related to, the performance of his services under this Agreement. The Consultant shall submit to the Company itemized monthly statements, in a form satisfactory to the Company, of such expenses incurred in the previous month. The Company shall pay to the Consultant amounts shown on each such statement within 30 days after receipt thereof.
		

		
			 
		

		
			3.4        Benefits. The Consultant shall not be entitled to any benefits, coverages or privileges, including, without limitation, social security, unemployment, medical or pension payments, made available to employees of the Company.
		

		
			 
		

		
			4.        Termination. The Company may, without prejudice to any right or remedy it may have due to any failure of the Consultant to perform his obligations under this Agreement, terminate the Consultation Period upon 30 days’ prior written notice to the Consultant. The Consultant may, without prejudice to any right or remedy it may have due to any failure of the Company to perform its obligations under this Agreement, terminate the Consultation Period upon 90 days’ prior written notice to the Company. In the event of such termination, the Consultant shall be entitled to payment for services performed and expenses paid or incurred prior to the effective date of termination, subject to the limitation on reimbursement of expenses set forth in Section 3.2. Such payments shall constitute full settlement of any and all claims of the Consultant of every description against the Company. Notwithstanding the foregoing, the Company may terminate the Consultation Period, effective immediately upon receipt of written notice, if the Consultant breaches or threatens to breach any provision of Section 6 or Section 7, and the Consultant may terminate the Consultation Period, effective immediately upon receipt of written notice, if the Company breaches any provision of Section 3. The provisions of Sections 4, 6, 7, 8, 10 and 14 shall survive any termination of this Agreement.
		

		
			 
		

		
			5.        Cooperation. The Consultant shall use his best efforts in the performance of his obligations under this Agreement.  The Company shall provide such access to its information and
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

 

		

		
			property as may be reasonably required in order to permit the Consultant to perform his obligations hereunder. The Consultant shall cooperate with the Company’s personnel, shall not interfere with the conduct of the Company’s business and shall observe all rules, regulations and security requirements of the Company concerning the safety of persons and property.
		

		
			 
		

		
			6.        Inventions and Proprietary Information.
		

		
			 
		

		
			6.1        Inventions.
		

		
			 
		

		
			(a)        All inventions, discoveries, computer programs, data, technology, designs, innovations and improvements (whether or not patentable and whether or not copyrightable) (“Inventions”) which are made, conceived, reduced to practice, created, written, designed or developed by the Consultant, solely or jointly with others and whether during normal business hours or otherwise, (i) during the Consultation Period that result from the performance of Consultant’s services and if related to the business of the Company or (ii) after the Consultation Period if resulting or directly derived from Proprietary Information (as defined below), shall be the sole property of the Company. The Consultant hereby assigns to the Company all Inventions and any and all related patents, copyrights, trademarks, trade names, and other industrial and intellectual property rights and applications therefor, in the United States and elsewhere and appoints any officer of the Company as his duly authorized attorney to execute, file, prosecute and protect the same before any government agency, court or authority. Upon the request of the Company and at the Company’s expense, the Consultant shall execute such further assignments, documents and other instruments as may be necessary or desirable to fully and completely assign all Inventions to the Company and to assist the Company in applying for, obtaining and enforcing patents or copyrights or other rights in the United States and in any foreign country with respect to any Invention.  The Consultant also hereby waives all claims to moral rights in any Inventions.
		

		
			 
		

		
			(b)        The Consultant shall promptly disclose to the Company all Inventions and will maintain adequate and current written records (in the form of notes, sketches, drawings and as may be specified by the Company) to document the conception and/or first actual reduction to practice of any Invention. Such written records shall be available to and remain the sole property of the Company at all times.
		

		
			 
		

		
			6.2        Proprietary Information.
		

		
			 
		

		
			(a)        The Consultant acknowledges that his relationship with the Company is one of high trust and confidence and that in the course of his service to the Company he will have access to and contact with Proprietary Information. The Consultant agrees that he will not, during the Consultation Period or at any time thereafter, disclose to others, or use for his benefit or the benefit of others, any Proprietary Information or Invention.
		

		
			 
		

		
			(b)        For purposes of this Agreement, Proprietary Information shall mean, by way of illustration and not limitation, all information (whether or not patentable and whether or not copyrightable) owned, possessed or used by the Company, including, without limitation, any Invention, formula, vendor information, customer information, apparatus, equipment, trade secret, process, research, report, technical data, know-how, computer program, software, software documentation, hardware design, technology, marketing or business plan, forecast, unpublished
		

		
			
		

		
			

		 

		

			3

		

 

		

		
			financial statement, budget, license, price, cost and employee list that is communicated to, learned of, developed or otherwise acquired by the Consultant in the course of his service as a consultant to the Company.
		

		
			 
		

		
			(c)        The Consultant’s obligations under this Section 6.2 shall not apply to any information (none of which shall be deemed Proprietary Information) that (i) was known to Consultant prior to it being furnished to the Consultant by or on behalf of the Company provided that such information was or is not known to Consultant to be subject to another confidentiality agreement with, or other contractual, legal or fiduciary obligation of confidentiality to the Company, (ii) is developed by Consultant independently of the Proprietary Information disclosed to Consultant by the Company as demonstrated by the Consultant through third party written records, (iii) is acquired by Consultant on a non-confidential basis from any person entitled to make disclosure to Consultant unless such person is under an obligation of confidentiality to Company which is known to Consultant, (iv) is or becomes known to the general public under circumstances involving no breach by the Consultant or others of the terms of this Section 6.2, (v) is generally disclosed to third parties by the Company without restriction on such third parties, (vi) is approved for release by written authorization of the Board of Directors of the Company, or (vii) Consultant is obligated to produce pursuant to an order of a court of competent jurisdiction or a valid administrative or Congressional subpoena, provided that the Consultant promptly notify Company and cooperate reasonably with Company’s efforts to contest or limit the scope of such order.
		

		
			 
		

		
			(d)        Upon termination of this Agreement or at any other time upon request by the Company, the Consultant shall promptly deliver to the Company all records, files, memoranda, notes, designs, data, reports, price lists, customer lists, drawings, plans, computer programs, software, software documentation, sketches, laboratory and research notebooks and other documents (and all copies or reproductions of such materials) relating to the business of the Company.
		

		
			 
		

		
			(e)        The Consultant represents that his retention as a consultant with the Company and his performance under this Agreement does not, and shall not, breach any agreement that obligates him to keep in confidence any trade secrets or confidential or proprietary information of his or of any other party or to refrain from competing, directly or indirectly, with the business of any other party. The Consultant shall not disclose to the Company any trade secrets or confidential or proprietary information of any other party.
		

		
			 
		

		
			(f)        The Consultant acknowledges that the Company from time to time may have agreements with other persons or with the United States Government, or agencies thereof, that impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. The Consultant agrees to be bound by all such obligations and restrictions that are known to him and to take all action necessary to discharge the obligations of the Company under such agreements.
		

		
			 
		

		
			7.        Non-Competition and Non-Solicitation.
		

		
			 
		

		
			7.1        Restrictions. During the term of this Agreement and for a period of one (1) year after termination of the Agreement, the Consultant will not directly or indirectly:
		

		
			
		

		
			

		 

		

			4

		

 

		

		
			(a)        Engage or assist others in engaging in any business or enterprise (whether as owner, partner, officer, director, employee, consultant, investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that is competitive with the Company’s business, including but not limited to any business or enterprise that develops, manufactures, markets, licenses, sells or provides any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or provided, or planned to be developed, manufactured, marketed, licensed, sold or provided, by the Company while the Consultant was employed by the Company; or
		

		
			 
		

		
			(b)        Either alone or in association with others, divert or take away, or attempt to divert or take away, the business or patronage of any of the clients, customers, or business partners of the Company which were contacted, solicited, or served by the Company during the 12-month period prior to the termination or cessation of the Consultant’s services with the Company; or
		

		
			 
		

		
			(c)        Either alone or in association with others (i) solicit, induce or attempt to induce, any employee or independent contractor of the Company to terminate his or her employment or other engagement with the Company, or (ii) hire, or recruit or attempt to hire, or engage or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by the Company at any time during the term of the Consultant’s services with the Company; provided, that this clause (ii) shall not apply to the recruitment or hiring or other engagement of any individual whose employment or other engagement with the Company has been terminated for a period of six months or longer.
		

		
			 
		

		
			7.2        Extension. If the Consultant violates the provisions of Section 7.1, the Consultant shall continue to be bound by the restrictions set forth in such paragraph until a period of one (1) year has expired without any violation of such provisions.
		

		
			 
		

		
			7.3        Company’s Business. For purposes of this Agreement, the “Company’s business” shall mean the discovery and development of therapeutic, diagnostic, and/or research products related to mechanisms by which gene transcription is regulated, provided, however, that the “Company’s business” shall exclude the discovery and development of therapeutic, diagnostic, and/or research products that target BET bromodomains and histone deacetylases 1, 2 and 6.
		

		
			 
		

		
			8.        Remedies. The Consultant acknowledges that any breach of the provisions of Section 6 or 7 could result in serious and irreparable injury to the Company for which the Company cannot be adequately compensated by monetary damages alone. The Consultant agrees, therefore, that in the event of such breach, in addition to any other remedy it may have, the Company shall be entitled to enforce the specific performance of this Agreement by the Consultant and to seek both temporary and permanent injunctive relief (to the extent permitted by law) without the necessity of proving actual damages.
		

		
			 
		

		
			9.        Independent Contractor Status. The Consultant shall perform all services under this Agreement as an “independent contractor” and not as an employee or agent of the Company. The Consultant is not authorized to assume or create any obligation or responsibility, express or implied, on behalf of, or in the name of, the Company or to bind the Company in any manner.
		

		
			
		

		
			

		 

		

			5

		

 

		

		
			10.        Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail, postage prepaid, addressed to the other party at the address shown above, or at such other address or addresses as either party shall designate to the other in accordance with this Section 10.
		

		
			 
		

		
			11.        Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.
		

		
			 
		

		
			12.        Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral, relating to the subject matter of this Agreement.
		

		
			 
		

		
			13.        Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Consultant.
		

		
			 
		

		
			14.        Governing Law. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the Commonwealth of Massachusetts.
		

		
			 
		

		
			15.        Successors and Assigns. This Agreement shall be binding upon, and inure to the benefit of, both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of the Consultant are personal and shall not be assigned by him.
		

		
			 
		

		
			16.        Miscellaneous.
		

		
			 
		

		
			16.1        No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.
		

		
			 
		

		
			16.2        The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. In the event that any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			[Remainder of page intentionally left blank]
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			6

		

 

		

		
			IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set forth above.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						LS22, Inc.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By: 

					
					
						/s/ Douglas Cole, M.D.

				
	
					
						 

					
					
						Name: Douglas Cole, M.D.

				
	
					
						 

					
					
						Title: President

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						CONSULTANT

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						/s/ Richard A. Young, Ph.D.

				
	
					
						 

					
					
						Richard A. Young, Ph.D.

				

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			Signature Page to Consulting Agreement
		

		
			 
		

		
			 
		

		
			

		 

		

			 

		

 

		

		
			WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH UNIFORM CONSULTING AGREEMENT PROVISIONS
		

		
			 
		

		
			1.     The Whitehead Institute for Biomedical Research (“WHITEHEAD”) is a non-profit biomedical research institute having a business address of Nine Cambridge Center, Cambridge, Massachusetts 02142. These Uniform Consulting Agreement Provisions (the “Uniform Provisions”) are attached to an agreement (the “Agreement”) under which a Member of WHITEHEAD (the “Consultant”) has agreed to provide consulting services to the company named in the Agreement (the “Company”). The Consultant and the Company agree that the Agreement shall have no force or effect unless these Uniform Provisions are signed by both parties and attached to the Agreement. By signing the Uniform Provisions, the Consultant and the Company agree to abide by them, and also agree that if anything in the Agreement is inconsistent with the Uniform Provisions, the Uniform Provisions shall govern.
		

		
			 
		

		
			2.     The Agreement shall disclose all compensation of whatever kind that is to be provided to the Consultant in connection with the consulting services. The Agreement shall disclose the time commitment for the consulting services, which may not exceed one day per week for all outside activities of the Member of WHITEHEAD.
		

		
			 
		

		
			3.     The Consultant’s services for the Company shall consist only of the exchange of ideas and provision of advice; the Consultant shall not direct or conduct research for or on behalf of the Company.
		

		
			 
		

		
			4.     The Company acknowledges that the Consultant is a Member of WHITEHEAD and is subject to WHITEHEAD’s policies, including policies concerning consulting, conflicts of interest, and intellectual property. In accordance with WHITEHEAD policy, the Consultant may disclose to the Company any information that the Consultant would normally freely disclose to other members of the scientific community at large, whether by publication, by presentation at seminars, or in informal scientific discussions. However, the Consultant shall not disclose to the Company information that (i) is proprietary to WHITEHEAD and (ii) is not generally available to the public, except through formal technology transfer procedures.
		

		
			 
		

		
			5.     Subject to the terms of paragraph 6, below, the Consultant may assign to the Company any right, title and interest the Consultant may have in any invention, discovery, improvement, or other intellectual property which the Consultant (whether alone or with others) develops (i) during the course of performing consulting services for the Company under the Agreement and (ii) outside the course of the Consultant’s activities as a Member of WHITEHEAD.
		

		
			 
		

		
			STANDARD CONSULTING AGREEMENT PROVISIONS
		

		
			Page 1 (Revised December 7, 2006)
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			6.     The Company shall have no rights by reason of the Agreement in any publication, invention, discovery, improvement, or other intellectual property whatsoever, whether or not publishable, patentable, or copyrightable, which is developed as a result of a program of research financed, in whole or in part, by funds provided by or under the control of WHITEHEAD. The Company also acknowledges and agrees that it will enjoy no priority or advantage as a result of the consultancy created by the Agreement in gaining access, whether by license or otherwise, to any proprietary information or intellectual property that arises from any research undertaken by the Consultant in his or her capacity as a Member of WHITEHEAD.
		

		
			 
		

		
			7.     The Company agrees, at its sole expense, to defend WHITEHEAD against, and to indemnify and hold WHITEHEAD harmless from, any claim, liability, judgment, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including without limitation reasonable attorneys’ fees and other costs and expenses of defense) relating to a claim or suit by a third party against WHITEHEAD, either arising from the Agreement, the Consultant’s performance of services for the Company under the Agreement, or any Company products or services which result from the Consultant’s performance of services under the Agreement.
		

		
			 
		

		
			8.     Nothing in the Agreement shall affect the Consultant’s right to use, disseminate, or publish any information that (i) is or becomes available to the public through no breach of the Agreement by the Consultant; (ii) is obtained by the Consultant from a third party who had the legal right to disclose the information to the Consultant; (iii) is already in the possession of the Consultant on the date the Agreement becomes effective; or (iv) is required to be disclosed by law, government regulation, or court order, provided that the Consultant takes reasonable steps to provide the Company with sufficient prior notice to allow the Company to consent to the disclosure or seek a protective order. In addition, the Company’s confidential information does not include information generated by the Consultant (whether alone or with others) unless the Consultant generated the information (i) during the course of performing consulting services for the Company under the Agreement and (ii) outside the course of the Consultant’s activities as a Member of WHITEHEAD.
		

		
			 
		

		
			9.     The Company acknowledges and agrees that nothing in the Agreement shall affect the Consultant’s obligations to WHITEHEAD, the Consultant’s research on behalf of WHITEHEAD, or research collaborations in which the Consultant is a participant, and that the Agreement shall have no effect upon transfers (by way of license or otherwise) to third parties of materials or intellectual property developed in whole or in part by the Consultant as a Member of WHITEHEAD.
		

		
			 
		

		
			10.     Paragraphs 7, 8, 9, 10, 12, 13, and 14 of these Uniform Provisions shall survive termination of the Agreement.
		

		
			 
		

		
			STANDARD CONSULTING AGREEMENT PROVISIONS
		

		
			Page 2 (Revised December 7, 2006)
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			11.   The Company may use the Consultant’s name, and in doing so may cite the Consultant’s relationship with WHITEHEAD, so long as any such usage (i) is limited to reporting factual events or occurrences only, and (ii) is made in a manner that could not reasonably constitute an endorsement of the Company or of any Company program, product or service. However, the Company shall not use the Consultant’s name or WHITEHEAD’s name in any press release, or quote the Consultant in any company materials, or otherwise use the Consultant’s name or WHITEHEAD’s name in a manner not specifically permitted by the preceding sentence, unless in each case the Company obtains in advance WHITEHEAD’s written consent, and, in the case of the use of the Consultant’s name, the Consultant’s consent as well.
		

		
			 
		

		
			12.   The Consultant and the Company acknowledge that (i) the Consultant is entering into the Agreement and these Uniform Provisions in the Consultant’s individual capacity and not as a Member of WHITEHEAD, (ii) WHITEHEAD is not a party to the Agreement or the Uniform Provisions and has no liability or obligation under them, and (iii) WHITEHEAD is an intended third-party beneficiary of the Agreement and the Uniform Provisions are for WHITEHEAD's benefit and are enforceable by WHITEHEAD in its own name.
		

		
			 
		

		
			13.    These Uniform Provisions shall be in effect for the full term of the Agreement. The Company and the Consultant agree that any amendment of the Agreement (including, without limitation, any extension of the Agreement's term or any change in the consideration to be provided to the Consultant under the Agreement) or any other departure from the terms or conditions of the Agreement must be signed by the Consultant and an authorized representative of the Company, and also is subject to WHITEHEAD's prior written approval.
		

		
			 
		

		
			14.   If any of these Uniform Provisions is adjudicated to be invalid, unenforceable, contrary to, or prohibited under applicable laws or regulations of any jurisdiction, the Agreement shall terminate as of the date such adjudication is effective.
		

		
			 
		

		
			COMPANY
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						By: 

					
					
						/s/ Douglas Cole

					
					
						 

				
	
					
						Name: Douglas Cole

					
					
						 

				
	
					
						Title: President

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						CONSULTANT

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						By:

					
					
						/s/ Richard A. Young

					
					
						 

				
	
					
						Name: Richard A. Young, Ph.D.

					
					
						 

				

		
			 
		

		
			 
		

		
			 
		

		
			STANDARD CONSULTING AGREEMENT PROVISIONS
		

		
			Page 3 (Revised December 7, 2006)
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			ANNEX 1
		

		
			 
		

		
			Existing Endeavors
		

		
			 
		

		
			1.        Presently engaged under consulting arrangements with:
		

		
			 
		

			
	
			
				 ·
			

			
	
			
			Enzon Pharmaceuticals, Inc.

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			STANDARD CONSULTING AGREEMENT PROVISIONS
		

		
			Page 4 (Revised December 7, 2006)
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			 
		

		
			CONSULTING AGREEMENT-FIRST AMENDMENT
		

		
			 
		

		
			This First Amendment to the CONSULTING AGREEMENT (the "First Amendment"), made this 3rd day of December, 2012 is entered into by Syros Pharmaceuticals, Inc. (f/k/a LS22, Inc.), a Delaware corporation with its principal place of business at One Memorial Drive, 7th.  Floor, Cambridge, MA 02142 (the "Company"), and Richard A. Young, Ph.D. (the "Consultant").
		

		
			 
		

		
			WHEREAS, Company and Consultant entered into a Consulting Agreement dated August 8, 2012 (the "Agreement"); and
		

		
			 
		

		
			WHEREAS, Company and Consultant desire to amend the Term of the Agreement under Section 2 and the Compensation under Section 3.
		

		
			 
		

		
			NOW THEREFORE, in consideration of the mutual covenants, conditions and agreements set forth herein, and for such other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
		

		
			 
		

		
			I. Defined Terms. Unless otherwise defined herein, the meaning of the terms used herein shall have the same meanings set forth in the Agreement.
		

		
			 
		

		
			2A. Term. Section 2 of the Agreement is deleted and replaced in its entirety with the following:
		

		
			 
		

		
			"2. Term. This Agreement shall commence July 3, 2012 and shall continue until July 3, 2016 (such period, as it may be extended, being referred to as the "Consultation Period"), unless sooner terminated in accordance with the provisions of Section 4."
		

		
			 
		

		
			2B. Fees.  Section 3.2 of the Agreement is deleted and replaced in its entirety with the following:
		

		
			 
		

		
			"3.2 Fees. The Company shall pay to the Consultant consulting fees of $75,000 per year, payable in equal quarterly installments.  Payment for any partial quarter shall be prorated.
		

		
			 
		

		
			Transaction Bonus. If, within eighteen (18) months from the date hereof, the Company signs an agreement with a Partner (as defined below) encompassing a Qualifying Transaction (as defined below), the Company shall pay to the Consultant a cash bonus of $125,000 within fifteen (15) days of the signing of such agreement. For purposes of this Agreement, "Partner" means any third party for-profit entity. For purposes of this Agreement, "Qualifying Transaction" means a transaction pursuant to which the consideration received by the Company will, in the reasonable judgment of the Board of Directors of the Company, exceed $50 million within two (2) years from the date of the agreement with the Partner."
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			 
		

		
			3.        Full Force and Effect. Except as expressly provided in this First Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein.
		

		
			 
		

		
			4.        Entire Agreement. This First Amendment together with the Agreement constitute the full and complete agreement and understanding between Company and Consultant concerning the subject matter hereof.
		

		
			 
		

		
			IN WITNESS WHEREOF,  Company and Consultant have caused this First Amendment to be executed by their duly authorized  officer as of the Effective Date.
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						SYROS PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By: 

					
					
						/s/ Nancy Simonian, M.D.

				
	
					
						 

					
					
						Nancy Simonian M.D.

				
	
					
						 

					
					
						CEO

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						CONSULTANT

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Richard A. Young, Ph.D.

				
	
					
						 

					
					
						Richard A. Young, Ph.D.

				

		
			 
		

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			 
		

		
			CONSULTING AGREEMENT- SECOND AMENDMENT
		

		
			 
		

		
			This Second Amendment to the CONSULTING AGREEMENT (the "Second Amendment"), dated as of September 29, 2016 (the "Agreement Date") and effective as of July 3, 2016, is entered into by Syros Pharmaceuticals, Inc. (f/k/a LS22, Inc.), a Delaware corporation with its principal place of business at 620 Memorial Drive, Suite 300, Cambridge, MA 02139 (the "Company"), and Richard A. Young, Ph.D. (the "Consultant").
		

		
			 
		

		
			WHEREAS, the Company and the Consultant entered into a Consulting Agreement dated August 8, 2012 (the "Original Agreement");
		

		
			 
		

		
			WHEREAS, the parties entered into that certain First Amendment dated December 3, 2012 (the "First Amendment"; and the Original Agreement, as amended by the First Amendment, the "Agreement"), to amend the term of the Original Agreement and the compensation to the Consultant set forth therein; and
		

		
			 
		

		
			WHEREAS, the Company and the Consultant desire to further amend the term of the Agreement under Section 2 and the compensation set forth under Section 3 as described herein.
		

		
			 
		

		
			NOW THEREFORE, in consideration of the mutual covenants, conditions and agreements set forth herein, and for such other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
		

		
			 
		

		
			1.        Defined Terms.  Unless otherwise defined herein, the meaning of the terms used herein shall have the same meanings set forth in the Agreement.
		

		
			 
		

		
			2.        Amendments to Agreement.  The Company and the Consultant agree that the Agreement shall be and hereby is amended as follows:
		

		
			 
		

		
			a.    Term. The reference to "July 3, 2016" in Section 2 of the Agreement shall be replaced by "July 3, 2019".
		

		
			 
		

		
			b.   Equity Compensation. Section 3.1 of the Agreement shall be deleted and replaced in its entirety with the following:
		

		
			 
		

		
			"3.1        Equity Compensation. In consideration for the performance of the services hereunder, the Consultant has been awarded (a) a grant of 1,600,000 shares of restricted common stock, $0.001 par value per share, of the Company ("Common Stock"), having a purchase price of $0.001, pursuant to that certain Restricted Stock Agreement dated as of August 8, 2012 and (b) an option to purchase 75,000 shares of Common Stock, with an exercise price equal to the fair market value of such options on the date of grant, vesting upon certain performance-based milestones approved by the Board of Directors of the Company and having such other terms and conditions as shall be set forth in an option grant agreement between the Consultant and the Company."
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			c.    Fees.  Section 3.2 of the Agreement shall be deleted and replaced in its entirety with the following:
		

		
			 
		

		
			"3.2 Fees. The Company shall pay to the Consultant consulting fees of $125,000 per year, payable in equal quarterly installments. Payment for any partial quarter shall be prorated."
		

		
			 
		

		
			3.        Full Force and Effect.  Except as expressly provided in this Second Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein.
		

		
			 
		

		
			4.        Entire Agreement.  This Second Amendment together with the Agreement constitute the full and complete agreement and understanding between the Company and the Consultant concerning the subject matter hereof.
		

		
			 
		

		
			 
		

		
			 
		

		
			[Remainder of page intentionally blank]
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			
		

		
			

		 

		

			 

		

 

		

		
			IN WITNESS WHEREOF, the Company and the Consultant have caused this Second Amendment to be executed  by their duly authorized  officer as of the Agreement Date.
		

		
			 
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						SYROS PHARMACEUTICALS, INC.

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By: 

					
					
						/s/ Nancy Simonian, M.D.

				
	
					
						 

					
					
						Nancy Simonian M.D.

				
	
					
						 

					
					
						CEO

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						CONSULTANT

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						/s/ Richard A. Young, Ph.D.

				
	
					
						 

					
					
						Richard A. Young, Ph.D.EX-10.1

 Exhibit 10.1 

SUPPORT AGREEMENT 
 This
SUPPORT AGREEMENT (this “Agreement”), dated as of March 19, 2017, is entered into by and among Daré Bioscience, Inc., a Delaware corporation (“Private Company”), and each Person set forth on Schedule
A hereto (each, a “Stockholder”). All capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Purchase Agreement (as defined below). 

WHEREAS, as of the date hereof, each Stockholder is the record and/or beneficial owner (as defined in Rule
13d-3 under the Exchange Act) of the number of shares of Public Company Common Stock, Public Company Warrants and Public Company Stock Options, in each case set forth opposite such Stockholder’s name on
Schedule A (all such shares, Public Company Warrants and Public Company Stock Options set forth on Schedule A next to such Stockholder’s name, together with any shares of Public Company Common Stock that are hereafter issued to or
otherwise directly or indirectly acquired by such Stockholder prior to the termination of this Agreement, including for the avoidance of doubt any shares of Public Company Common Stock acquired by such Stockholder upon the exercise of Public Company
Warrants or Public Company Stock Options after the date hereof, being referred to herein as such Stockholder’s “Subject Shares”); 

WHEREAS, concurrently with the execution hereof, Private Company, the equityholders of Private Company and Cerulean Pharma Inc., a Delaware
corporation (“Public Company”), are entering into a Stock Purchase Agreement, dated as of the date hereof (as it may be amended pursuant to the terms thereof, the “Purchase Agreement”), which provides, among other
things, for Public Company to purchase all of the outstanding shares of Private Company Common Stock in consideration of the issuance of Public Company Common Stock to the holders of Private Company Common Stock, upon the terms and subject to the
conditions set forth in the Purchase Agreement; and 
 WHEREAS, as a condition to its willingness to enter into the Purchase Agreement, and
as an inducement and in consideration for Private Company to enter into the Purchase Agreement, each Stockholder, severally and not jointly, and on such Stockholder’s own account with respect to such Stockholder’s Subject Shares, has
agreed to enter into this Agreement. 
 NOW, THEREFORE, in consideration of the foregoing and the respective representations, warranties,
covenants and agreements set forth herein, the Private Company and the Stockholders, intending to be legally bound, hereby agree as follows: 

ARTICLE I 
 AGREEMENT TO
VOTE; NO TRANSFER; NO INCONSISTENT ARRANGEMENTS 
 1.1.    Agreement to
Vote. Subject to the terms of this Agreement, each Stockholder hereby irrevocably and unconditionally agrees that, during the time this Agreement is in effect, at any annual or special meeting of the stockholders of the Company,
however called, including any adjournment or postponement thereof, such Stockholder shall, in each case to the fullest extent that such Stockholder’s Subject Shares are entitled to vote thereon, be present (in person or by proxy) and vote (or
cause to be voted) such Stockholder’s Subject Shares in favor 

 
of the Public Company Voting Proposal, against any Acquisition Proposal and against any other action, agreement or transaction involving the Company that would reasonably be expected to impede,
delay or prevent the consummation of the Transaction. Each Stockholder shall retain at all times the right to vote the Subject Shares in such Stockholder’s sole discretion, and without any other limitation, on any matters other than those set
forth in Section 1.1 that are at any time or from time to time presented for consideration to Public Company’s stockholders 

1.2.    Grant of Proxy. Each Stockholder hereby appoints the Chief
Executive Officer of the Private Company as such Stockholder’s attorney-in-fact and proxy with full power of substitution, to vote or execute written consents with
respect to such Stockholder’s Subject Shares, solely on the matters and in the manner specified in Section 1.1. This proxy shall be valid during the term of this Agreement. 

1.3.    Proxy Irrevocable. THE PROXIES AND POWERS OF ATTORNEY GRANTED PURSUANT TO THE
ABOVE SECTION 1.2 ARE IRREVOCABLE DURING THE TERM OF THIS AGREEMENT AND COUPLED WITH AN INTEREST. Each Stockholder hereby revokes all other proxies and powers of attorney on the matters specified in Section 1.1 with respect to such
Stockholder’s Subject Shares that such Stockholder may have heretofore appointed or granted, and no subsequent proxy or power of attorney shall be given or written consent executed (and if given or executed, shall not be effective) by such
Stockholder with respect to such Stockholder’s Subject Shares that is inconsistent with this Agreement. All authority herein conferred or agreed to be conferred shall survive the death or incapacity of any Stockholder and any obligation of any
Stockholder under this Agreement shall be binding upon the heirs, personal representatives and successors of such Stockholder. 

1.4.    No Transfer; No Inconsistent
Arrangements. Except as provided hereunder or under the Purchase Agreement, from and after the date hereof and until this Agreement is terminated, such Stockholder shall not, directly or indirectly, (a) create or permit to
exist any Lien, other than any Lien created by this Agreement or any restriction on transfer under any applicable securities law, on any of such Stockholder’s Subject Shares, (b) transfer, sell, assign, gift, hedge, pledge or otherwise
dispose of (collectively, “Transfer”) any of such Stockholder’s Subject Shares, (c) grant any proxy or power-of-attorney with respect to any
of such Stockholder’s Subject Shares, (d) deposit any of such Stockholder’s Subject Shares into a voting trust or enter into a voting agreement or arrangement with respect to any of such Stockholder’s Subject Shares, or
(f) take any other action that would interfere with the performance of such Stockholder’s obligations hereunder or otherwise make any representation or warranty of such Stockholder herein untrue or incorrect. Notwithstanding the foregoing,
any Stockholder may Transfer Subject Shares (i) to any member of such Stockholder’s immediate family, (ii) to a charitable organization, (iii) to a trust for the sole benefit of such Stockholder or any member of such
Stockholder’s immediate family, the sole trustees of which are such Stockholder or any member of such Stockholder’s immediate family, or (iv) by will or under the laws of intestacy upon the death of such Stockholder; provided,
that a transfer referred to in clause (i) through (iv) of this sentence shall be permitted only if the transferee agrees in writing to accept such Subject Shares subject to the terms of this Agreement and to be bound by the terms of this
Agreement and to agree and acknowledge that such transferee shall constitute a Stockholder for all purposes of this Agreement. If any involuntary Transfer of any of such Stockholder’s Subject Shares in the Company shall occur (including, but
not limited to, a sale by such Stockholder’s trustee in any bankruptcy, 

  
 -2- 

 
or a sale to a purchaser at any creditor’s or court sale), the transferee (which term, as used herein, shall include any and all transferees and subsequent transferees of the initial
transferee) shall take and hold such Subject Shares subject to all of the restrictions, liabilities and rights under this Agreement, which shall continue in full force and effect until valid termination of this Agreement. Notwithstanding the
foregoing, such Stockholder may make Transfers of its Subject Shares as Private Company may agree in writing in its sole discretion. 

1.5    Further Assurances. Subject to the terms and conditions set forth in this
Agreement, from time to time upon the Private Company’s or the Public Company’s request, each Stockholder will execute any further agreement or form reasonably necessary or appropriate to confirm and effectuate the grant of the proxy
contained in Section 1.2. 
 ARTICLE II 

REPRESENTATIONS AND WARRANTIES OF EACH STOCKHOLDER 

Each Stockholder represents and warrants, on such Stockholder’s own account with respect to the Subject Shares, to Private Company as to
such Stockholder on a several basis, that: 
 2.1.    Organization; Authorization;
Binding Agreement. If such Stockholder is not an individual, such Stockholder is duly organized, validly existing in good standing under the laws of the jurisdiction in which it is organized, and the execution,
delivery of this Agreement by such Stockholder and the consummation of the transactions contemplated hereby by such Stockholder are within such Stockholder’s entity powers and have been duly authorized by all necessary entity actions on the
part of such Stockholder. If such Stockholder is an individual, such Stockholder has full legal capacity, right and authority to execute and deliver this Agreement and consummate the transactions contemplated hereby. This Agreement has been duly
executed and delivered by such Stockholder and constitutes the valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance with its terms, subject to the Bankruptcy and Equity Exception. 

2.2.    Non-Contravention. Neither the execution and delivery of
this Agreement by such Stockholder nor the consummation of the transactions contemplated hereby by such Stockholder will (a) if such Stockholder is not an individual, conflict with, or result in a breach or violation of, any provision of
the certificate of incorporation or bylaws or other organization document of such Stockholder, (b) conflict with, or result in any violation or breach of, or constitute (with or without notice or lapse of time, or both) a default (or give
rise to a right of termination, cancellation or acceleration of any obligation or loss of any material benefit) under, require a consent or waiver under, require the payment of a penalty under or result in the imposition of any Lien on such
Stockholder’s Subject Shares under, any of the terms, conditions or provisions of any lease, license, contract or other agreement, instrument or obligation to which such Stockholder is a party or by which such Stockholder or any of its
properties or assets may be bound or (c) require any consent, approval, license, permit order or authorization of, or registration, declaration, notice or filing with, any Governmental Entity, except for compliance with the applicable
requirements of the Securities Act, the Exchange Act or any other securities laws and the rules and regulations promulgated thereunder, and except as would not, in the case of each of clauses (b) and (c), reasonably be expected to have,
individually or in the aggregate, a material adverse effect on such Stockholder’s ability to timely perform its obligations under this Agreement. 

  
 -3- 

 2.3.    Ownership of
Subject Shares;. Such Stockholder is the record and/or beneficial owner (as defined in Rule 13d-3 under the Exchange Act) of all such Stockholder’s Subject Shares
and has good and valid title to all such Subject Shares free and clear of any Liens, except for any Liens that may be imposed pursuant to this Agreement and any restrictions on transfer under applicable securities laws. 

2.4.    Voting Power. Such Stockholder has full voting power (to the extent such
Subject Shares have voting power), and sole dispositive power, with respect to all such Stockholder’s Subject Shares. 

2.5.    Reliance. Such Stockholder understands and acknowledges that Private Company is entering into the
Purchase Agreement in reliance upon such Stockholder’s execution, delivery and performance of this Agreement. 
 ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF PRIVATE COMPANY 

Private Company represents and warrants to the Stockholders that: 

3.1.    Organization. Private Company is duly organized, validly existing and in good standing under the
laws of the jurisdiction in which it is organized. 
 3.2.    Authority; Binding
Agreement. The execution, delivery of this Agreement by Private Company and the consummation of the transactions contemplated hereby by Private Company are within its entity powers and have been duly authorized by all necessary
entity actions on the part of it. This Agreement has been duly executed and delivered by Private Company and constitutes the valid and binding obligation of Private Company, enforceable against Private Company in accordance with its terms, subject
to the Bankruptcy and Equity Exception. 

3.3.    Non-Contravention. Neither the execution and delivery of
this Agreement by Private Company nor the consummation of the transactions contemplated hereby by Private Company will (a) conflict with, or result in a breach or violation of, any provision of the certificate of incorporation or bylaws or
other organization document of Private Company, (b) conflict with, or result in any violation or breach of, or constitute (with or without notice or lapse of time, or both) a default (or give rise to a right of termination, cancellation or
acceleration of any obligation or loss of any material benefit) under, require a consent or waiver under, require the payment of a penalty under or result in the imposition of any Lien on Private Company’s assets under, any of the terms,
conditions or provisions of any lease, license, contract or other agreement, instrument or obligation to which Private Company is a party or by which any of the properties or assets of Private Company may be bound, (c) require any consent,
approval, license, permit order or authorization of, or registration, declaration, notice or filing with, any Governmental Entity, except for compliance with the applicable requirements of the Securities Act, the Exchange Act or any other securities
laws and the rules and regulations promulgated thereunder, and except as would not, in the case of each of clauses (b) and (c), reasonably be expected to have, individually or in the aggregate, a material adverse effect on the Private
Company’s ability to timely perform its obligations under this Agreement. 

  
 -4- 

 ARTICLE IV 

MISCELLANEOUS 

4.1.    Termination. This Agreement shall terminate automatically with respect to a Stockholder, without any
notice or other action by any Person, upon the first to occur of (a) the valid termination of the Purchase Agreement in accordance with its terms, (b) the Closing, (c) the entry without the prior written consent of such Stockholder
into any amendment or modification to the Purchase Agreement or any waiver of any of Public Company’s rights under the Purchase Agreement, in each case, that results in an increase in the Exchange Ratio (as defined in the Purchase Agreement on
the date hereof), which, for clarification, shall not include any adjustment to the Exchange Ratio that may result from the mechanics set forth in the Purchase Agreement as such agreement exists on the date hereof, or (d) the mutual written
consent of Private Company and such Stockholder. In the event of termination of this Agreement, this Agreement shall immediately become void and there shall be no liability or obligation on the part of any party hereto or their respective
Representatives, stockholders or Affiliates; provided that, (i) any such termination shall not relieve any party hereto from liability for any material breach of any covenant or agreement set forth in this Agreement that is a consequence
of any act, or failure to act, undertaken by the breaching party with the knowledge that the taking of such act, or failure to act, would result in such breach and (ii) the provisions of this Article IV (Miscellaneous) shall remain in
full force and effect and survive any termination of this Agreement. 
 4.2.    Amendments. This Agreement
may not be amended except by an instrument in writing signed on behalf of each of the parties hereto. 

4.3.    Extension; Waiver. The parties hereto may, to the extent legally allowed,
(a) extend the time for the performance of any of the obligations or other acts of the other parties hereto, (b) waive any inaccuracies in the representations and warranties contained herein or in any document delivered pursuant hereto and
(c) waive compliance with any of the agreements or conditions contained herein. Any agreement on the part of a party hereto to any such extension or waiver shall be valid only if set forth in a written instrument signed on behalf of such party.
Such extension or waiver shall not apply to any time for performance, inaccuracy in any representation or warranty, or noncompliance with any agreement or condition, as the case may be, other than that which is specified in the extension or waiver.
The failure of any party hereto to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights. 

4.4.    Notices. All notices and other communications hereunder shall be in writing and shall be deemed duly
delivered (a) four Business Days after being sent by registered or certified mail, return receipt requested, postage prepaid, (b) one Business Day after being sent for next Business Day delivery, fees prepaid, via a reputable nationwide
overnight courier service, or (c) on the date of confirmation of receipt (or, the first Business Day following such receipt if the date of such receipt is not a Business Day) of transmission by facsimile or electronic mail, in each case to the
intended recipient; provided that the notice or other communication is sent to the address, facsimile number or email address set forth (i) if to Private Company, to the 

  
 -5- 

 
address, facsimile number or e-mail address set forth in Section 10.2 of the Purchase Agreement and (ii) if to a Stockholder, to such
Stockholder’s address, facsimile number or e-mail address set forth on a signature page hereto, or to such other address, facsimile number or e-mail address as such
party may hereafter specify for the purpose by notice to each other party hereto. 
 4.5.    Entire
Agreement. This Agreement (including Schedule A) constitutes the entire agreement among the parties hereto and supersedes any prior understandings, agreements or representations by or among the parties hereto, or any of
them, written or oral, with respect to the subject matter hereof, and the parties hereto specifically disclaim reliance on any such prior understandings, agreements or representations to the extent not embodied in this Agreement. 

4.6.    Third Party Beneficiaries. This Agreement is not intended
to, and shall not, confer upon any other Person any rights or remedies hereunder. 
 4.7.    Assignment.
Neither this Agreement nor any of the rights, interests or obligations under this Agreement may be assigned or delegated, in whole or in part, by operation of law or otherwise by any of the parties hereto without the prior written consent of the
other parties, and any such assignment without such prior written consent shall be null and void. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of, and be enforceable by, the parties hereto and their
respective successors and permitted assigns. 
 4.8.    Severability. Any term or provision (or part
thereof) of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions (or parts thereof) hereof or the validity or enforceability of the
offending term or provision (or part thereof) in any other situation or in any other jurisdiction. If the final judgment of a court of competent jurisdiction declares that any term or provision (or part thereof) hereof is invalid or unenforceable,
the court making such determination shall have the power to limit the term or provision (or part thereof), to delete specific words or phrases, or to replace any invalid or unenforceable term or provision (or part thereof) with a term or provision
(or part thereof) that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision (or part thereof), and this Agreement shall be enforceable as so modified. In the event such court
does not exercise the power granted to it in the prior sentence, the parties hereto shall replace such invalid or unenforceable term or provision (or part thereof) with a valid and enforceable term or provision (or part thereof) that will achieve,
to the extent possible, the economic, business and other purposes of such invalid or unenforceable term (or part thereof). 

4.9.    Counterparts and Signature. This Agreement may be executed
in two or more counterparts (including by facsimile or by an electronic scan delivered by electronic mail), each of which shall be deemed an original but all of which together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each of the parties hereto and delivered to the other parties, it being understood that all parties need not sign the same counterpart. This Agreement may be executed and delivered by facsimile or by an
electronic scan delivered by electronic mail. 

  
 -6- 

 4.10.    Interpretation. Except where expressly stated
otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) “either” and “or” are not exclusive and “include”, “includes” and “including” are not limiting; (b)
“hereof”, “hereto”, “hereby”, “herein” and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this
Agreement; (c) “date hereof” refers to the date set forth in the initial caption of this Agreement; (d) “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase
does not mean simply “if”; (e) descriptive headings, the table of defined terms and the table of contents are inserted for convenience only and do not affect in any way the meaning or interpretation of this Agreement; (f) definitions
contained in this Agreement are applicable to the singular as well as the plural forms of such terms; (g) references to a Person are also to its permitted successors and assigns; (h) references to an “Article”,
“Section”, “Recital”, “introductory paragraph”, “Annex”, “Exhibit” or “Schedule” refer to an Article, Section, Recital or introductory paragraph of, or an Annex, Exhibit or Schedule to,
this Agreement; (i) references to “$” or otherwise to dollar amounts refer to the lawful currency of the United States; (j) references to a federal, state, local or foreign statute or law include any rules, regulations and
delegated legislation issued thereunder; and (k) references to a communication by a regulatory agency include a communication by the staff of such regulatory agency. The language used in this Agreement shall be deemed to be the language chosen
by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party hereto. No summary of this Agreement prepared by any party shall affect the meaning or interpretation of this Agreement. 

4.11.    Governing Law. This Agreement shall be governed by and construed in accordance
with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdictions
other than those of the State of Delaware. 
 4.12.    Remedies. 

(a)    Except as otherwise provided herein, any and all remedies herein expressly conferred upon a Person will be deemed
cumulative with and not exclusive of any other remedy conferred hereby, or by law or equity upon such Person, and the exercise by a Person of any one remedy will not preclude the exercise of any other remedy. 

(b)    Irreparable damage would occur in the event that any provision of this Agreement were not performed in accordance
with its specific terms or were otherwise breached, as money damages or other legal remedies would not be an adequate remedy for any such damages. Accordingly, in the event of any breach or threatened breach by any Stockholder, on the one hand, or
Private Company, on the other hand, of any of their respective covenants or obligations set forth in this Agreement, each Stockholder, on the one hand, and Private Company, on the other hand, shall be entitled to an injunction or injunctions to
prevent or restrain breaches or threatened breaches of this Agreement, by the other (as applicable), and to specifically enforce the terms and provisions of this Agreement to prevent breaches or 

  
 -7- 

 
threatened breaches of, or to enforce compliance with, the covenants and obligations of the other under this Agreement, in each case without posting a bond or other security. No party hereto
shall raise any objections to the availability of the equitable remedy of specific performance to prevent or restrain breaches or threatened breaches of this Agreement by Private Company, or to specifically enforce the terms and provisions of this
Agreement to prevent breaches or threatened breaches of, or to enforce compliance with, the covenants and obligations of Private Company under this Agreement. Time shall be of the essence for purposes of this Agreement. 

4.13.    Submission to Jurisdiction. Each of the parties hereto
(a) consents to submit itself to the exclusive personal jurisdiction of the Court of Chancery of the State of Delaware, New Castle County, or, if that court does not have jurisdiction, a federal court sitting in the State of Delaware in any
action or proceeding arising out of or relating to this Agreement or any of the transactions contemplated by this Agreement, (b) agrees that all claims in respect of such action or proceeding shall be heard and determined in any such court,
(c) agrees that it shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, and (d) agrees not to bring any action or proceeding arising out of or relating to this Agreement
or any of the transaction contemplated by this Agreement in any other court. Each of the parties hereto waives any defense of inconvenient forum to the maintenance of any action or proceeding so brought and waives any bond, surety or other security
that might be required of any other Person with respect thereto. Any party hereto may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of
notices in Section 4.4 Nothing in this Section 4.13, however, shall affect the right of any Person to serve legal process in any other manner permitted by law. 

4.14.    Capacity as Stockholder. Each Stockholder signs this
Agreement solely in such Stockholder’s capacity as a stockholder of the Company, and not in such Stockholder’s capacity as a director, officer or employee of the Company. Notwithstanding anything herein to the contrary, nothing herein
shall in any way restrict a director or officer of the Company in the taking of any actions (or failure to act) in his or her capacity as a director or officer of the Company, or in the exercise of his or her fiduciary duties as a director or
officer of the Company, or prevent or be construed to create any obligation on the part of any director or officer of the Company from taking any action in his or her capacity as such director or officer, and no action taken in any such capacity as
an officer or director of the Company shall be deemed to constitute a breach of this Agreement. 

4.15.    No Agreement Until Executed. This
Agreement shall not be effective unless and until (i) the Purchase Agreement is executed by all parties thereto and (ii) this Agreement is executed by all parties hereto. 

4.16.    Stockholder Obligation Several
and Not Joint. The obligations of each Stockholder hereunder shall be several and not joint, and no Stockholder shall be liable for any breach of the terms of this Agreement by any other
Stockholder. 
 [Remainder of Page Intentionally Left Blank. Signature Pages Follow.] 

  
 -8- 

 The parties are executing this Agreement on the date set forth in the introductory clause. 

 

							
		 		 	 DARÉ BIOSCIENCE, INC.

				
		 		 	By:	 	 /s/ Sabrina Martucci Johnson

		 		 		 	 Sabrina Martucci Johnson, CEO

 [Signature Page to Support Agreement] 

 
					
	STOCKHOLDERS
	
	POLARIS VENTURE PARTNERS IV, L.P
		
	By:	 	 Polaris Venture Management
 Co. IV,
L.L.C., its General Partner

			
		 	By:	 	 /s/ Max Eisenberg

		 		 	Max Eisenberg
		 		 	Attorney-in-fact
	
	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND IV, L.P.
		
	By:	 	 Polaris Venture Management
 Co. IV,
L.L.C., its General Partner

			
		 	By:	 	 /s/ Max Eisenberg

		 		 	Max Eisenberg
		 		 	Attorney-in-fact
	
	POLARIS VENTURE PARTNERS V, L.P
		
	By:	 	 Polaris Venture Management
 Co. V,
L.L.C., its General Partner

			
		 	By:	 	 /s/ Max Eisenberg

		 		 	Max Eisenberg
		 		 	Attorney-in-fact

 [Signature Page to Support Agreement] 

 
					
	POLARIS VENTURE PARTNERS ENTREPRENEURS’ FUND V, L.P.
		
	By:	 	 Polaris Venture Management
 Co. V,
L.L.C., its General Partner

			
		 	By: 	 	 /s/ Max Eisenberg

		 		 	Max Eisenberg
		 		 	Attorney-in-fact
	
	POLARIS VENTURE PARTNERS FOUNDERS’ FUND V, L.P.
		
	By:	 	 Polaris Venture Management
 Co. V,
L.L.C., its General Partner

			
		 	By:	 	 /s/ Max Eisenberg

		 		 	Max Eisenberg
		 		 	Attorney-in-fact
	
	POLARIS VENTURE PARTNERS SPECIAL FOUNDERS’ FUND V, L.P
		
	By:	 	 Polaris Venture Management
 Co. V,
L.L.C., its General Partner

			
		 	By:	 	 /s/ Max Eisenberg

		 		 	Max Eisenberg
		 		 	Attorney-in-fact

  
 [Signature Page to
Support Agreement] 

 
			
	 STOCKHOLDER

	
	 /s/ Stuart A. Arbuckle

	Name:	 	Stuart A. Arbuckle

  

			
	Stockholder Address for Notices:
	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	STOCKHOLDER
	
	 /s/ Alan Crane

	Name:	 	Alan Crane

  

			
	Stockholder Address for Notices:
	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	 STOCKHOLDER

	
	 /s/ Paul A. Friedman

	Name:	 	Paul A. Friedman

  

			
	 Stockholder Address for Notices:

	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	 STOCKHOLDER

	
	 /s/ Christopher D. T. Guiffre

	Name:	 	Christopher D. T. Guiffre

  

			
	 Stockholder Address for Notices:

	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	 STOCKHOLDER

	
	 /s/ Susan L. Kelley

	Name:	 	

  

			
	 Stockholder Address for Notices:

	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	 STOCKHOLDER

	
	 /s/ William T. McKee

	Name:	 	William T. McKee

  

			
	 Stockholder Address for Notices:

	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	STOCKHOLDER
	
	 /s/ David Ross Parkinson

	Name:	 	

  

			
	Stockholder Address for Notices:
	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	STOCKHOLDER
	
	 /s/ William Rastetter

	Name:	 	William Rastetter

  

			
	Stockholder Address for Notices:
	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 
			
	STOCKHOLDER
	
	 /s/ David R. Walt

	Name:	 	David R. Walt

  

			
	Stockholder Address for Notices:
	
	  

	
	  

	
	  

		
	E-mail:	 	  

		
	Facsimile:	 	  

  
 [Signature Page to
Support Agreement] 

 Schedule A 

 

													
	 Name of Stockholder
	  	Number of
Shares of
Company
Common
Stock	 	  	Company
Stock
Options	 	  	Company
Warrants	 
	 Stuart A. Arbuckle
	  	 	13,104	 	  	 	42,000	 	  			
	 Alan L. Crane
	  	 	4,857,206	 	  	 	64,232	 	  	 	30,430	 
	 Paul A. Friedman
	  	 	8,546	 	  	 	153,000	 	  			
	 Christopher D.T. Guiffre
	  	 	12,489	 	  	 	861,977	 	  			
	 Susan L. Kelley
	  				  	 	53,000	 	  			
	 William T. McKee
	  	 	3,418	 	  	 	53,000	 	  			
	 David R. Parkinson
	  	 	28,488	 	  	 	53,000	 	  			
	 Polaris Venture Partners Entrepreneurs Fund V, L.P.
	  	 	61,353	 	  				  	 	471	 
	 Polaris Venture Partners Entrepreneurs’ Fund IV, L.P.
	  	 	26,351	 	  				  	 	98	 
	 Polaris Venture Partners Founders’ Fund V, L.P.
	  	 	21,562	 	  				  	 	165	 
	 Polaris Venture Partners IV, L.P.
	  	 	1,405,750	 	  				  	 	5,242	 
	 Polaris Venture Partners Special Founders’ Fund V, L.P.
	  	 	31,478	 	  				  	 	241	 
	 Polaris Venture Partners V, L.P.
	  	 	3,148,044	 	  				  	 	24,213	 
	 William H. Rastetter
	  	 	103,039	 	  	 	53,000	 	  	 	379	 
	 David R. Walt
	  	 	193,700	 	  	 	42,000	 	  			

 [Schedule A to Support Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]